Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial

Authors:

Abstract
No abstract available
Funding Information
  • Blood Cancer UK
  • Janssen Pharmaceutica

This publication has 11 references indexed in Scilit: